REGENXBIO - Stock Price History | RGNX

Historical daily share price chart and data for REGENXBIO since 2021 adjusted for splits. The latest closing stock price for REGENXBIO as of October 26, 2021 is 35.98.
  • The all-time high REGENXBIO stock closing price was 82.15 on July 10, 2018.
  • The REGENXBIO 52-week high stock price is 50.26, which is 39.7% above the current share price.
  • The REGENXBIO 52-week low stock price is 27.02, which is 24.9% below the current share price.
  • The average REGENXBIO stock price for the last 52 weeks is 37.82.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
REGENXBIO Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 36.5798 38.9900 54.2000 21.5000 45.3600 10.72%
2019 44.7959 43.3300 62.4500 31.8400 40.9700 -2.34%
2018 52.0580 34.7500 82.1500 24.0500 41.9500 26.17%
2017 22.8349 18.5000 34.6000 16.7000 33.2500 79.25%
2016 13.4967 17.0000 24.0000 7.3200 18.5500 11.75%
2015 20.6147 30.4500 30.7000 14.1500 16.6000 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.533B $0.155B
REGENXBIO Inc. is a biotechnology company. The Company focuses on the development, commercialization and licensing of recombinant adeno-associated virus gene therapy. Its products candidates include RGX-501, for the treatment of homozygous familial hypercholesterolemia which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; RGX-111, for the treatment of Mucopolysaccharidosis Type I which uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system; RGX-121, for the treatment of Mucopolysaccharidosis Type II; RGX-314, for the treatment of wet age-related macular degeneration and RGX-321, for the treatment of X-linked retinitis pigmentosa. REGENXBIO Inc. is headquartered in Rockville, Maryland.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.416B 8.62
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.526B 21.21
Biohaven Pharmaceutical Holding (BHVN) United States $9.249B 0.00
Emergent Biosolutions (EBS) United States $2.705B 6.53
Arcus Biosciences (RCUS) United States $2.404B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.873B 0.00
Myovant Sciences (MYOV) United Kingdom $1.831B 0.00
Zymeworks (ZYME) Canada $1.080B 0.00
Ambrx Biopharma (AMAM) United States $0.464B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.161B 15.86